Lipid rafts, pseudotyping, and virus-like particles: Relevance of a novel, configurable, and modular antigen-presenting platform

International Archives of Allergy and Immunology

Volumn 154, Issue 2, 2011, Pages 89-110

  Kueng, Hans J ^a   Schmetterer, Klaus G ^a   Pickl, Winfried F ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE FOR MICROELECTRONICS   (Austria)

Author keywords

Antigen presentation; Lipid rafts; Pseudotyping; Virus like particles

Indexed keywords

CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ADAPTIVE IMMUNITY; ALLERGIC DISEASE; ANTIGEN PRESENTING CELL; CD8+ T LYMPHOCYTE; CELL MEMBRANE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LIPID RAFT; NONHUMAN; PRIORITY JOURNAL; PSEUDOTYPING; REVIEW; SYNAPSE; T LYMPHOCYTE; VIRUS PARTICLE;

ANTIGEN PRESENTATION; HUMANS; IMMUNOLOGICAL SYNAPSES; LYMPHOCYTE ACTIVATION; MEMBRANE MICRODOMAINS; T-LYMPHOCYTES; VIRION;

EID: 77956077262     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320224     Document Type: Review

References (359)

1. Medzhitov R, Janeway CA Jr: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol 1997; 9: 4-9.
2. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 1996; 272: 50-53.
3. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
4. Steinman RM, Witmer MD: Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 1978; 75: 5132-5136.
5. Macatonia SE, Taylor PM, Knight SC, Askonas BA: Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 1989; 169: 1255-1264.
6. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-365.
7. Schuler G, Steinman RM: Dendritic cells as adjuvants for immune-mediated resistance to tumors. J Exp Med 1997; 186: 1183-1187.
8. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190: 1669-1678.
9. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T: Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
10. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G: Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-1288.
11. Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H: Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 1999; 169: 45-54.
12. Lu L, Thomson AW: Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation 2002; 73:S19-S22.
13. Larche M, Akdis CA, Valenta R: Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6: 761-771.
14. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J: GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992; 360: 258-261.
15. Pickl WF, Majdic O, Kohl P, Stockl J, Riedl E, Scheinecker C, Bello-Fernandez C, Knapp W: Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 1996; 157: 3850-3859.
16. Reid CD, Fryer PR, Clifford C, Kirk A, Tikerpae J, Knight SC: Identification of hematopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 1990; 76: 1139-1149.
17. Strunk D, Rappersberger K, Egger C, Strobl H, Kromer E, Elbe A, Maurer D, Stingl G: Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996; 87: 1292-1302.
18. Fong L, Engleman EG: Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273.
19. Vulink A, Radford KJ, Melief C, Hart DN: Dendritic cells in cancer immunotherapy. Adv Cancer Res 2008; 99: 363-407.
20. Coyle AJ, Gutierrez-Ramos JC: The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2001; 2: 203-209.
21. Lanzavecchia A, Sallusto F: Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2001; 2: 487-492.
22. Montoya MC, Sancho D, Vicente-Manzanares M, Sanchez-Madrid F: Cell adhesion and polarity during immune interactions. Immunol Rev 2002; 186: 68-82.
23. Bretscher P, Cohn M: A theory of self-nonself discrimination. Science 1970; 169: 1042-1049.
24. Lafferty KJ, Cunningham AJ: A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci 1975; 53: 27-42.
25. Eckels DD, Sell TW, Bronson SR, Johnson AH, Hartzman RJ, Lamb JR: Human helper T-cell clones that recognize different influenza hemagglutinin determinants are restricted by different HLA-D region epitopes. Immunogenetics 1984; 19: 409-423.
26. Shevach EM, Rosenthal AS: Function of macrophages in antigen recognition by guinea pig T lymphocytes. II. Role of the macrophage in the regulation of genetic control of the immune response. J Exp Med 1973; 138: 1213-1229.
27. Zinkernagel RM, Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974; 248: 701-702.
28. Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF: Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 1999; 162: 3256-3262.
29. Setterblad N, Becart S, Charron D, Mooney N: B cell lipid rafts regulate both peptide-dependent and peptide-independent APC-T cell interaction. J Immunol 2004; 173: 1876-1886.
30. Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science 1991; 254: 1016-1019.
31. Tavano R, Contento RL, Baranda SJ, Soligo M, Tuosto L, Manes S, Viola A: CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse. Nat Cell Biol 2006; 8: 1270-1276.
32. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A: T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999; 283: 680-682.
33. Anderson HA, Hiltbold EM, Roche PA: Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat Immunol 2000; 1: 156-162.
34. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A: Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 1998; 395: 82-86.
35. Viola A, Lanzavecchia A: T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-106.
36. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ: Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180: 631-640.
37. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA: ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 1999; 397: 263-266.
38. Krensky AM, Sanchez-Madrid F, Robbins E, Nagy JA, Springer TA, Burakoff SJ: The functional significance, distribution, and structure of LFA-1, LFA-2, and LFA-3: cell surface antigens associated with CTL-target interactions. J Immunol 1983; 131: 611-616.
39. Stuber E, Strober W: The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996; 183: 979-989.
40. Cai Z, Sprent J: Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro. J Exp Med 1996; 183: 2247-2257.
41. Carreno BM, Collins M: The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20: 29-53.
42. Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23: 23-68.
43. Brunet JF, Denizot F, Luciani MF, Roux- Dosseto M, Suzan M, Mattei MG, Golstein P: A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987; 328: 267-270.
44. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
45. Nishimura H, Minato N, Nakano T, Honjo T: Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998; 10: 1563-1572.
46. Ragazzo JL, Ozaki ME, Karlsson L, Peterson PA, Webb SR: Costimulation via lymphocyte function-associated antigen 1 in the absence of CD28 ligation promotes anergy of naive CD4+ T cells. Proc Natl Acad Sci USA 2001; 98: 241-246.
47. Schwartz RH: T cell anergy. Annu Rev Immunol 2003; 21: 305-334.
48. Vella AT, Mitchell T, Groth B, Linsley PS, Green JM, Thompson CB, Kappler JW, Marrack P: CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol 1997; 158: 4714-4720.
49. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF: Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005; 174: 4465-4469.
50. Kurt-Jones EA, Hamberg S, Ohara J, Paul WE, Abbas AK: Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness. J Exp Med 1987; 166: 1774-1787.
51. Valenzuela J, Schmidt C, Mescher M: The roles of IL-12 in providing a third signal for clonal expansion of naive CD8 T cells. J Immunol 2002; 169: 6842-6849.
52. Conlon PJ, Morrissey PJ, Nordan RP, Grabstein KH, Prickett KS, Reed SG, Goodwin R, Cosman D, Namen AE: Murine thymocytes proliferate in direct response to interleukin- 7. Blood 1989; 74: 1368-1373.
53. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin- 2 receptor. Science 1994; 264: 965-968. (Pubitemid 24196167)
54. Morgan DA, Ruscetti FW, Gallo R: Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-1008.
55. Ohara J, Paul WE: Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature 1987; 325: 537-540.
56. Akdis CA, Blaser K: IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J 1999; 13: 603-609.
57. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGFbeta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
58. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS: Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037-1050.
59. Dooms H, Wolslegel K, Lin P, Abbas AK: Interleukin- 2 enhances CD4+ T cell memory by promoting the generation of IL-7R alphaexpressing cells. J Exp Med 2007; 204: 547-557.
60. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK: Biochemical mechanisms of IL- 2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8: 615-623.
61. Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-793.
62. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-2357.
63. Maggi E, Parronchi P, Manetti R, Simonelli C, Piccinni MP, Rugiu FS, De Carli M, Ricci M, Romagnani S: Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992; 148: 2142-2147.
64. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S: Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 1199-1204.
65. Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP, Macchia D, Maggi E, Del Prete G, Romagnani S: IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992; 149: 2977-2983.
66. Tang L, Benjaponpitak S, DeKruyff RH, Umetsu DT: Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production. J Allergy Clin Immunol 1998; 102: 428-435.
67. Dignani MC, Rex JH, Chan KW, Dow G, deMagalhaes-Silverman M, Maddox A, Walsh T, Anaissie E: Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 2005; 104: 199-204.
68. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ: Reengineering dendritic cellbased anti-cancer vaccines. Immunol Rev 2008; 222: 256-276.
69. Murray HW: Cytokines as antimicrobial therapy for the T cell-deficient patient: prospects for treatment of nonviral opportunistic infections. Clin Infect Dis 1993; 17(suppl 2):S407-S413.
70. Spolski R, Leonard WJ: The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol 2008; 20: 295-301.
71. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH: Immunotherapy of cancer by IL- 12-based cytokine combinations. Expert Opin Biol Ther 2007; 7: 1705-1721.
72. Audibert FM, Lise LD: Adjuvants: current status, clinical perspectives and future prospects. Trends Pharmacol Sci 1993; 14: 174-178.
73. Gupta RK, Siber GR: Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995; 13: 1263-1276.
74. Bryant M, Ratner L: Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1990; 87: 523-527.
75. Graham DR, Chertova E, Hilburn JM, Arthur LO, Hildreth JE: Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts. J Virol 2003; 77: 8237-8248.
76. Laliberte JP, McGinnes LW, Peeples ME, Morrison TG: Integrity of membrane lipid rafts is necessary for the ordered assembly and release of infectious Newcastle disease virus particles. J Virol 2006; 80: 10652-10662.
77. Manie SN, de Breyne S, Vincent S, Gerlier D: Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly. J Virol 2000; 74: 305-311.
78. Nguyen DH, Hildreth JE: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000; 74: 3264-3272.
79. Pickl WF, Pimentel-Muinos FX, Seed B: Lipid rafts and pseudotyping. J Virol 2001; 75: 7175-7183.
80. Scheiffele P, Roth MG, Simons K: Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J 1997; 16: 5501-5508.
81. Pape KA, Khoruts A, Mondino A, Jenkins MK: Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol 1997; 159: 591-598.
82. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997; 387: 569-572.
83. Guerriero CJ, Lai Y, Weisz OA: Differential sorting and Golgi export requirements for raft-associated and raft-independent apical proteins along the biosynthetic pathway. J Biol Chem 2008; 283: 18040-18047.
84. Nichols BJ, Lippincott-Schwartz J: Endocytosis without clathrin coats. Trends Cell Biol 2001; 11: 406-412.
85. Keller P, Simons K: Cholesterol is required for surface transport of influenza virus hemagglutinin. J Cell Biol 1998; 140: 1357-1367.
86. Subtil A, Gaidarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE: Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA 1999; 96: 6775-6780.
87. Wang Y, Thiele C, Huttner WB: Cholesterol is required for the formation of regulated and constitutive secretory vesicles from the trans-Golgi network. Traffic 2000; 1: 952-962.
88. Xavier R, Brennan T, Li Q, McCormack C, Seed B: Membrane compartmentation is required for efficient T cell activation. Immunity 1998; 8: 723-732.
89. Brown DA, London E: Structure and origin of ordered lipid domains in biological membranes. J Membr Biol 1998; 164: 103-114.
90. Radhakrishnan A, McConnell HM: Condensed complexes of cholesterol and phospholipids. Biophys J 1999; 77: 1507-1517.
91. Brown DA: Interactions between GPIanchored proteins and membrane lipids. Trends Cell Biol 1992; 2: 338-343.
92. Legler DF, Doucey MA, Schneider P, Chapatte L, Bender FC, Bron C: Differential insertion of GPI-anchored GFPs into lipid rafts of live cells. FASEB J 2005; 19: 73-75.
93. Paulick MG, Bertozzi CR: The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry 2008; 47: 6991-7000.
94. Bijlmakers MJ: Protein acylation and localization in T cell signaling (Review). Mol Membr Biol 2009; 26: 93-103.
95. Horejsi V: The roles of membrane microdomains (rafts) in T cell activation. Immunol Rev 2003; 191: 148-164.
96. Resh MD: Membrane targeting of lipid modified signal transduction proteins. Subcell Biochem 2004; 37: 217-232.
97. Resh MD: Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci STKE 2006; 2006:re14.
98. Douglass AD, Vale RD: Single-molecule microscopy reveals plasma membrane microdomains created by protein-protein networks that exclude or trap signaling molecules in T cells. Cell 2005; 121: 937-950.
99. Hancock JF: Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006; 7: 456-462.
100. Larson DR, Gosse JA, Holowka DA, Baird BA, Webb WW: Temporally resolved interactions between antigen-stimulated IgE receptors and Lyn kinase on living cells. J Cell Biol 2005; 171: 527-536.
101. Kusumi A, Ike H, Nakada C, Murase K, Fujiwara T: Single-molecule tracking of membrane molecules: plasma membrane compartmentalization and dynamic assembly of raft-philic signaling molecules. Semin Immunol 2005; 17: 3-21.
102. Kusumi A, Koyama-Honda I, Suzuki K: Molecular dynamics and interactions for creation of stimulation-induced stabilized rafts from small unstable steady-state rafts. Traffic 2004; 5: 213-230.
103. Mayor S, Rao M: Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 2004; 5: 231-240.
104. Sharma P, Varma R, Sarasij RC, Ira, Gousset K, Krishnamoorthy G, Rao M, Mayor S: Nanoscale organization of multiple GPIanchored proteins in living cell membranes. Cell 2004; 116: 577-589.
105. Dietrich C, Volovyk ZN, Levi M, Thompson NL, Jacobson K: Partitioning of Thy-1, GM1, and cross-linked phospholipid analogs into lipid rafts reconstituted in supported model membrane monolayers. Proc Natl Acad Sci USA 2001; 98: 10642-10647.
106. Kahya N, Brown DA, Schwille P: Raft partitioning and dynamic behavior of human placental alkaline phosphatase in giant unilamellar vesicles. Biochemistry 2005; 44: 7479-7489.
107. Simons K, Vaz WL: Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct 2004; 33: 269-295.
108. Anderson RG: Caveolae: where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 1993; 90: 10909-10913.
109. Delacour D, Jacob R: Apical protein transport. Cell Mol Life Sci 2006; 63: 2491-2505.
110. Kirkham M, Parton RG: Clathrin-independent endocytosis: new insights into caveolae and non-caveolar lipid raft carriers. Biochim Biophys Acta 2005; 1746: 349-363.
111. Paladino S, Sarnataro D, Pillich R, Tivodar S, Nitsch L, Zurzolo C: Protein oligomerization modulates raft partitioning and apical sorting of GPI-anchored proteins. J Cell Biol 2004; 167: 699-709.
112. Gaus K, Chklovskaia E, Fazekas de St Groth B, Jessup W, Harder T: Condensation of the plasma membrane at the site of T lymphocyte activation. J Cell Biol 2005; 171: 121-131.
113. Gupta N, DeFranco AL: Lipid rafts and B cell signaling. Semin Cell Dev Biol 2007; 18: 616-626.
114. Horejsi V, Drbal K, Cebecauer M, Cerny J, Brdicka T, Angelisova P, Stockinger H: GPImicrodomains: a role in signalling via immunoreceptors. Immunol Today 1999; 20: 356-361.
115. Xavier R, Seed B: Membrane compartmentation and the response to antigen. Curr Opin Immunol 1999; 11: 265-269.
116. Arreaza G, Brown DA: Sorting and intracellular trafficking of a glycosylphosphatidylinositol- anchored protein and two hybrid transmembrane proteins with the same ectodomain in Madin-Darby canine kidney epithelial cells. J Biol Chem 1995; 270: 23641-23647.
117. Butikofer P, Kuypers FA, Xu CM, Chiu DT, Lubin B: Enrichment of two glycosyl-phosphatidylinositol- anchored proteins, acetylcholinesterase and decay accelerating factor, in vesicles released from human red blood cells. Blood 1989; 74: 1481-1485.
118. Brewis IA, Ferguson MA, Mehlert A, Turner AJ, Hooper NM: Structures of the glycosyl-phosphatidylinositol anchors of porcine and human renal membrane dipeptidase: comprehensive structural studies on the porcine anchor and interspecies comparison of the glycan core structures. J Biol Chem 1995; 270: 22946-22956.
119. Dustin ML, Selvaraj P, Mattaliano RJ, Springer TA: Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface. Nature 1987; 329: 846-848. (Pubitemid 17152215)
120. Treumann A, Lifely MR, Schneider P, Ferguson MA: Primary structure of CD52. J Biol Chem 1995; 270: 6088-6099.
121. Simmons DL, Tan S, Tenen DG, Nicholson- Weller A, Seed B: Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 1989; 73: 284-289.
122. Shen F, Ross JF, Wang X, Ratnam M: Identification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificity. Biochemistry 1994; 33: 1209-1215.
123. Simmons D, Seed B: The Fc gamma receptor of natural killer cells is a phospholipidlinked membrane protein. Nature 1988; 333: 568-570.
124. Ratnoff WD, Knez JJ, Prince GM, Okada H, Lachmann PJ, Medof ME: Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol 1992; 87: 415-421.
125. Brown DA, Crise B, Rose JK: Mechanism of membrane anchoring affects polarized expression of two proteins in MDCK cells. Science 1989; 245: 1499-1501.
126. Lisanti MP, Caras IW, Davitz MA, Rodriguez- Boulan E: A glycophospholipid membrane anchor acts as an apical targeting signal in polarized epithelial cells. J Cell Biol 1989; 109: 2145-2156.
127. Alland L, Peseckis SM, Atherton RE, Berthiaume L, Resh MD: Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. J Biol Chem 1994; 269: 16701-16705.
128. Arcaro A, Gregoire C, Bakker TR, Baldi L, Jordan M, Goffin L, Boucheron N, Wurm F, van der Merwe PA, Malissen B, Luescher IF: CD8beta endows CD8 with efficient coreceptor function by coupling T cell receptor/ CD3 to raft-associated CD8/p56(lck) complexes. J Exp Med 2001; 194: 1485-1495.
129. Arcaro A, Gregoire C, Boucheron N, Stotz S, Palmer E, Malissen B, Luescher IF: Essential role of CD8 palmitoylation in CD8 coreceptor function. J Immunol 2000; 165: 2068-2076.
130. Crise B, Rose JK: Identification of palmitoylation sites on CD4, the human immunodeficiency virus receptor. J Biol Chem 1992; 267: 13593-13597.
131. Draberova L, Draber P: Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/ p56lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells. Proc Natl Acad Sci USA 1993; 90: 3611-3615.
132. Resh MD: Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta 1999; 1451: 1-16.
133. van't Hof W, Resh MD: Dual fatty acylation of p59(Fyn) is required for association with the T cell receptor zeta chain through phosphotyrosine- Src homology domain-2 interactions. J Cell Biol 1999; 145: 377-389.
134. Derdak SV, Kueng HJ, Leb VM, Neunkirchner A, Schmetterer KG, Bielek E, Majdic O, Knapp W, Seed B, Pickl WF: Direct stimulation of T lymphocytes by immunosomes: virus-like particles decorated with T cell receptor/ CD3 ligands plus costimulatory molecules. Proc Natl Acad Sci USA 2006; 103: 13144-13149.
135. Kueng HJ, Leb VM, Haiderer D, Raposo G, Thery C, Derdak SV, Schmetterer KG, Neunkirchner A, Sillaber C, Seed B, Pickl WF: General strategy for decoration of enveloped viruses with functionally active lipid-modified cytokines. J Virol 2007; 81: 8666-8676.
136. Kueng HJ, Manta C, Haiderer D, Leb VM, Schmetterer KG, Neunkirchner A, Byrne RA, Scheinecker C, Steinberger P, Seed B, Pickl WF: Fluorosomes: a convenient new reagent to detect and block multivalent and complex receptor-ligand interactions. FASEB J 2010; 24: 1572-1582.
137. Leb VM, Jahn-Schmid B, Kueng HJ, Schmetterer KG, Haiderer D, Neunkirchner A, Fischer GF, Hartl A, Thalhamer J, Steinberger P, Bohle B, Seed B, Pickl WF: Modulation of allergen-specific T-lymphocyte function by virus-like particles decorated with HLA class II molecules. J Allergy Clin Immunol 2009; 124: 121-128.
138. Leb VM, Jahn-Schmid B, Schmetterer KG, Kueng HJ, Haiderer D, Neunkirchner A, Fischer GF, Nissler K, Hartl A, Thalhamer J, Bohle B, Seed B, Pickl WF: Molecular and functional analysis of the antigen receptor of Art v 1-specific helper T lymphocytes. J Allergy Clin Immunol 2008; 121: 64-71.
139. Huttner WB, Zimmerberg J: Implications of lipid microdomains for membrane curvature, budding and fission. Curr Opin Cell Biol 2001; 13: 478-484.
140. Barman S, Nayak DP: Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft asso ciation. J Virol 2000; 74: 6538-6545.
141. Zhang J, Leser GP, Pekosz A, Lamb RA: The cytoplasmic tails of the influenza virus spike glycoproteins are required for normal genome packaging. Virology 2000; 269: 325-334. (Pubitemid 30210905)
142. Scheiffele P, Rietveld A, Wilk T, Simons K: Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem 1999; 274: 2038-2044.
143. Pepinsky RB, Vogt VM: Fine-structure analyses of lipid-protein and protein-protein interactions of gag protein p19 of the avian sarcoma and leukemia viruses by cyanogen bromide mapping. J Virol 1984; 52: 145-153.
144. Hansen M, Jelinek L, Whiting S, Barklis E: Transport and assembly of gag proteins into Moloney murine leukemia virus. J Virol 1990; 64: 5306-5316.
145. Fu X, Phillips N, Jentoft J, Tuazon PT, Traugh JA, Leis J: Site-specific phosphorylation of avian retrovirus nucleocapsid protein pp12 regulates binding to viral RNA: evidence for different protein conformations. J Biol Chem 1985; 260: 9941-9947.
146. Gottlinger HG: The HIV-1 assembly machine. AIDS 2001; 15(suppl 5):S13-S20.
147. Lindwasser OW, Resh MD: Multimerization of human immunodeficiency virus type 1 Gag promotes its localization to barges, raft-like membrane microdomains. J Virol 2001; 75: 7913-7924.
148. Ono A, Freed EO: Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001; 98: 13925-13930.
149. Rein A, McClure MR, Rice NR, Luftig RB, Schultz AM: Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc Natl Acad Sci USA 1986; 83: 7246-7250.
150. Schultz AM, Rein A: Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J Virol 1989; 63: 2370-2373.
151. Yuan B, Campbell S, Bacharach E, Rein A, Goff SP: Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J Virol 2000; 74: 7250-7260.
152. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA: Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci USA 1991; 88: 3195-3199.
153. King JA, Bridger JM, Gounari F, Lichter P, Schulz TF, Schirrmacher V, Khazaie K: The extended packaging sequence of MoMLV contains a constitutive mRNA nuclear export function. FEBS Lett 1998; 434: 367-371.
154. Camus G, Segura-Morales C, Molle D, Lopez- Verges S, Begon-Pescia C, Cazevieille C, Schu P, Bertrand E, Berlioz-Torrent C, Basyuk E: The clathrin adaptor complex AP-1 binds HIV-1 and MLV Gag and facilitates their budding. Mol Biol Cell 2007; 18: 3193-3203.
155. Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz PD: Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci USA 2003; 100: 12414-12419.
156. Martin-Serrano J, Zang T, Bieniasz PD: Role of ESCRT-I in retroviral budding. J Virol 2003; 77: 4794-4804.
157. Zhadina M, McClure MO, Johnson MC, Bieniasz PD: Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci USA 2007; 104: 20031-20036.
158. Huang AS, Palma EL, Hewlett N, Roizman B: Pseudotype formation between enveloped RNA and DNA viruses. Nature 1974; 252: 743-745.
159. Zavada J: Pseudotypes of vesicular stomatitis virus with the coat of murine leukaemia and of avian myeloblastosis viruses. J Gen Virol 1972; 15: 183-191.
160. Arthur LO, Bess JW Jr, Sowder RC 2nd, Benveniste RE, Mann DL, Chermann JC, Henderson LE: Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992; 258: 1935-1938.
161. Cantin R, Fortin JF, Lamontagne G, Tremblay M: The acquisition of host-derived major histocompatibility complex class II glycoproteins by human immunodeficiency virus type 1 accelerates the process of virus entry and infection in human T-lymphoid cells. Blood 1997; 90: 1091-1100.
162. Fortin JF, Cantin R, Lamontagne G, Tremblay M: Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997; 71: 3588-3596.
163. Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M: Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses: human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 1995; 155: 4376-4381.
164. Young JA, Bates P, Willert K, Varmus HE: Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 1990; 250: 1421-1423.
165. Pfistershammer K, Klauser C, Pickl WF, Stockl J, Leitner J, Zlabinger G, Majdic O, Steinberger P: No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. Eur J Immunol 2006; 36: 1104-1113.
166. Thery C, Zitvogel L, Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579.
167. van Niel G, Porto-Carreiro I, Simoes S, Raposo G: Exosomes: a common pathway for a specialized function. J Biochem 2006; 140: 13-21.
168. Malek TR: The biology of interleukin-2. Annu Rev Immunol 2008; 26: 453-479.
169. Malek TR, Bayer AL: Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4: 665-674.
170. Waldmann TA: The biology of interleukin- 2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6: 595-601.
171. Zhou LJ, Tedder TF: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 1996; 93: 2588-2592.
172. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ: CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353-1362.
173. Eren E, Yates J, Cwynarski K, Preston S, Dong R, Germain C, Lechler R, Huby R, Ritter M, Lombardi G: Location of major histocompatibility complex class II molecules in rafts on dendritic cells enhances the efficiency of T-cell activation and proliferation. Scand J Immunol 2006; 63: 7-16.
174. Hiltbold EM, Poloso NJ, Roche PA: MHC class II-peptide complexes and APC lipid rafts accumulate at the immunological synapse. J Immunol 2003; 170: 1329-1338.
175. Abdel Motal UM, Sentman CL, Zhou X, Robinson PJ, Dahmen J, Jondal M: Glycosylphosphatidylinositol- linked Db does not induce an influenza-specific cytotoxic T lymphocyte response or recycle membrane- bound peptides. Eur J Immunol 1995; 25: 1121-1124.
176. Sentman CL, Olsson-Alheim MY, Lendahl U, Karre K: Influence of glycosylphosphatidylinositol- linked H-2Dd molecules on target cell protection and natural killer cell specificity in transgenic mice. Eur J Immunol 1996; 26: 2127-2132.
177. Derdak SV: Immunosomes - T Cell Stimulation by Novel Multi-Purpose Antigen- Presenting Platforms; thesis, Medical University of Vienna, 2003.
178. Pircher H, Burki K, Lang R, Hengartner H, Zinkernagel RM: Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989; 342: 559-561.
179. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: Sensitive and viable identification of antigenspecific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65-78.
180. Riddell SR: Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med 2004; 200: 1533-1537.
181. Riddell SR, Greenberg PD: Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13: 545-586.
182. Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res 1991; 51: 5074s-5079s.
183. Ostrand-Rosenberg S: CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest 2005; 23: 413-419.
184. Gascan H, Gauchat JF, Aversa G, Van Vlasselaer P, de Vries JE: Anti-CD40 monoclonal antibodies or CD4+ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J Immunol 1991; 147: 8-13.
185. Gascan H, Gauchat JF, Roncarolo MG, Yssel H, Spits H, de Vries JE: Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991; 173: 747-750.
186. Geha RS, Schneeberger E, Rosen FS, Merler E: Interaction of human thymus-derived and non-thymus-derived lymphocytes in vitro. Induction of proliferation and antibody synthesis in B lymphocytes by a soluble factor released from antigen-stimulated T lymphocytes. J Exp Med 1973; 138: 1230-1247.
187. Coffman RL, Carty J: A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 1986; 136: 949-954.
188. Romagnani S: Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004; 113: 395-400.
189. Bettelli E, Korn T, Oukka M, Kuchroo VK: Induction and effector functions of T(H)17 cells. Nature 2008; 453: 1051-1057.
190. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
191. Gershon RK, Kondo K: Infectious immunological tolerance. Immunology 1971; 21: 903-914.
192. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742.
193. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
194. Weiner HL: The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol 2001; 2: 671-672.
195. Jiang S, Lechler RI: CD4+CD25+ regulatory T-cell therapy for allergy, autoimmune disease and transplant rejection. Inflamm Allergy Drug Targets 2006; 5: 239-242.
196. Saloga J, Bellinghausen I, Knop J: Do Tr1 cells play a role in immunotherapy? Int Arch Allergy Immunol 1999; 118: 210-211.
197. Himly M, Jahn-Schmid B, Dedic A, Kelemen P, Wopfner N, Altmann F, van Ree R, Briza P, Richter K, Ebner C, Ferreira F: Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensinlike and a hydroxyproline-rich domain. FASEB J 2003; 17: 106-108.
198. Jahn-Schmid B, Fischer GF, Bohle B, Fae I, Gadermaier G, Dedic A, Ferreira F, Ebner C: Antigen presentation of the immunodominant T-cell epitope of the major mugwort pollen allergen, Art v 1, is associated with the expression of HLA-DRB1 * 01. J Allergy Clin Immunol 2005; 115: 399-404.
199. Jahn-Schmid B, Kelemen P, Himly M, Bohle B, Fischer G, Ferreira F, Ebner C: The T cell response to Art v 1, the major mugwort pollen allergen, is dominated by one epitope. J Immunol 2002; 169: 6005-6011.
200. Jahn-Schmid B, Sirven P, Leb V, Pickl WF, Fischer GF, Gadermaier G, Egger M, Ebner C, Ferreira F, Maillere B, Bohle B: Characterization of HLA class II/peptide-TCR interactions of the immunodominant T cell epitope in Art v 1, the major mugwort pollen allergen. J Immunol 2008; 181: 3636-3642.
201. van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F: Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci USA 1997; 94: 7499-7502.
202. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA 1993; 90: 6586-6590.
203. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 1990; 248: 1349-1356.
204. Dalai SK, Mirshahidi S, Morrot A, Zavala F, Sadegh-Nasseri S: Anergy in memory CD4+ T cells is induced by B cells. J Immunol 2008; 181: 3221-3231.
205. Dure M, Macian F: IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes. Mol Immunol 2009; 46: 999-1006.
206. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A: Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002; 109: 719-731.
207. Zha Y, Marks R, Ho AW, Peterson AC, Janardhan S, Brown I, Praveen K, Stang S, Stone JC, Gajewski TF: T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 2006; 7: 1166-1173.
208. Lanier LL, O'Fallon S, Somoza C, Phillips JH, Linsley PS, Okumura K, Ito D, Azuma M: CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol 1995; 154: 97-105.
209. Parra E, Wingren AG, Hedlund G, Bjorklund M, Sjogren HO, Kalland T, Sansom D, Dohlsten M: Costimulation of human CD4+ T lymphocytes with B7 and lymphocyte function-associated antigen-3 results in distinct cell activation profiles. J Immunol 1994; 153: 2479-2487.
210. Wakkach A, Cottrez F, Groux H: Differentiation of regulatory T cells 1 is induced by CD2 costimulation. J Immunol 2001; 167: 3107-3113.
211. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K: Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102: 98-106.
212. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J: Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom- allergic subjects. Eur J Immunol 1997; 27: 1131-1139.
213. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR: Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154: 4187-4194.
214. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP: Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003; 421: 388-392.
215. Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE, Weiner HL: IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol 2009; 183: 2435-2443.
216. Tax WJ, Hermes FF, Willems RW, Capel PJ, Koene RA: Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation. J Immunol 1984; 133: 1185-1189.
217. Fewtrell C, Metzger H: Larger oligomers of IgE are more effective than dimers in stimulating rat basophilic leukemia cells. J Immunol 1980; 125: 701-710.
218. Minguet S, Swamy M, Alarcon B, Luescher IF, Schamel WW: Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity 2007; 26: 43-54.
219. Mossman KD, Campi G, Groves JT, Dustin ML: Altered TCR signaling from geometrically repatterned immunological synapses. Science 2005; 310: 1191-1193.
220. Ratcliffe MJ, Coggeshall KM, Newell MK, Julius MH: T cell receptor aggregation, but not dimerization, induces increased cytosolic calcium concentrations and reveals a lack of stable association between CD4 and the T cell receptor. J Immunol 1992; 148: 1643-1651.
221. Torigoe C, Inman JK, Metzger H: An unusual mechanism for ligand antagonism. Science 1998; 281: 568-572.
222. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML: The immunological synapse: a molecular machine controlling T cell activation. Science 1999; 285: 221-227. (Pubitemid 29329988)
223. Hafeman DG, von Tscharner V, McConnell HM: Specific antibody-dependent interactions between macrophages and lipid haptens in planar lipid monolayers. Proc Natl Acad Sci USA 1981; 78: 4552-4556.
224. Groves JT, Dustin ML: Supported planar bilayers in studies on immune cell adhesion and communication. J Immunol Methods 2003; 278: 19-32.
225. McConnell HM, Watts TH, Weis RM, Brian AA: Supported planar membranes in studies of cell-cell recognition in the immune system. Biochim Biophys Acta 1986; 864: 95-106.
226. Groves JT, Boxer SG: Micropattern formation in supported lipid membranes. Acc Chem Res 2002; 35: 149-157.
227. Sackmann E: Supported membranes: scientific and practical applications. Science 1996; 271: 43-48.
228. Medof ME, Nagarajan S, Tykocinski ML: Cell-surface engineering with GPI-anchored proteins. FASEB J 1996; 10: 574-586.
229. Metzner C, Salmons B, Gunzburg WH, Dangerfield JA: Rafts, anchors and viruses - a role for glycosylphosphatidylinositol anchored proteins in the modification of enveloped viruses and viral vectors. Virology 2008; 382: 125-131.
230. Herrmann SH, Weinberger O, Burakoff SJ, Mescher MF: Analysis of the two-signal requirement for precursor cytolytic T lymphocyte activation using H-2Kk in liposomes. J Immunol 1982; 128: 1968-1974.
231. Mescher MF: Surface contact requirements for activation of cytotoxic T lymphocytes. J Immunol 1992; 149: 2402-2405.
232. Prakken B, Wauben M, Genini D, Samodal R, Barnett J, Mendivil A, Leoni L, Albani S: Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat Med 2000; 6: 1406-1410.
233. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH: Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997; 159: 5921-5930.
234. Levine BL, Bernstein WB, Aronson NE, Schlienger K, Cotte J, Perfetto S, Humphries MJ, Ratto-Kim S, Birx DL, Steffens C, Landay A, Carroll RG, June CH: Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med 2002; 8: 47-53.
235. Rieu S, Geminard C, Rabesandratana H, Sainte-Marie J, Vidal M: Exosomes released during reticulocyte maturation bind to fibronectin via integrin alpha4beta1. Eur J Biochem 2000; 267: 583-590.
236. van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N, Heyman M: Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001; 121: 337-349.
237. Faure J, Lachenal G, Court M, Hirrlinger J, Chatellard-Causse C, Blot B, Grange J, Schoehn G, Goldberg Y, Boyer V, Kirchhoff F, Raposo G, Garin J, Sadoul R: Exosomes are released by cultured cortical neurones. Mol Cell Neurosci 2006; 31: 642-648.
238. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigenpresenting vesicles. J Exp Med 1996; 183: 1161-1172.
239. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, Hivroz C: TCR activation of human T cells induces the production of exosomes bearing the TCR/ CD3/zeta complex. J Immunol 2002; 168: 3235-3241.
240. Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, Namane A, Mecheri S: Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 2001; 166: 868-876.
241. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
242. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7: 297-303.
243. Blanc L, De Gassart A, Geminard C, Bette- Bobillo P, Vidal M: Exosome release by reticulocytes - an integral part of the red blood cell differentiation system. Blood Cells Mol Dis 2005; 35: 21-26.
244. Liu S, Stolz DB, Sappington PL, Macias CA, Killeen ME, Tenhunen JJ, Delude RL, Fink MP: HMGB1 is secreted by immunostimulated enterocytes and contributes to cytomix- induced hyperpermeability of Caco-2 monolayers. Am J Physiol Cell Physiol 2006; 290:C990-C999.
245. Segura E, Nicco C, Lombard B, Veron P, Raposo G, Batteux F, Amigorena S, Thery C: ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive Tcell priming. Blood 2005; 106: 216-223.
246. Thery C, Duban L, Segura E, Veron P, Lantz O, Amigorena S: Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol 2002; 3: 1156-1162.
247. Vincent-Schneider H, Stumptner-Cuvelette P, Lankar D, Pain S, Raposo G, Benaroch P, Bonnerot C: Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol 2002; 14: 713-722.
248. Admyre C, Johansson SM, Paulie S, Gabrielsson S: Direct exosome stimulation of peripheral human T cells detected by ELISPOT. Eur J Immunol 2006; 36: 1772-1781.
249. Admyre C, Bohle B, Johansson SM, Focke- Tejkl M, Valenta R, Scheynius A, Gabrielsson S: B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2- like cytokines. J Allergy Clin Immunol 2007; 120: 1418-1424.
250. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996; 196: 121-135. (Pubitemid 26306734)
251. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
252. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
253. Palucka AK, Ueno H, Fay J, Banchereau J: Dendritic cells: a critical player in cancer therapy? J Immunother 2008; 31: 793-805.
254. Rubio MT, Ittelet D, Raymond E, Blay JY, Bernard J, Chouaib S: The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. Int J Oncol 2004; 25: 407-412.
255. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685-711.
256. Adorini L, Penna G: Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol 2009; 188: 251-273.
257. Buckland M, Lombardi G: Aspirin and the induction of tolerance by dendritic cells. Handb Exp Pharmacol 2009; 188: 197-213.
258. Fischer R, Turnquist HR, Taner T, Thomson AW: Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 2009; 188: 215-232.
259. van Kooten C, Stax AS, Woltman AM, Gelderman KA: Handbook of experimental pharmacology 'dendritic cells': the use of dexamethasone in the induction of tolerogenic DCs. Handb Exp Pharmacol 2009; 188: 233-249.
260. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH: Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213-1222.
261. Sato K, Yamashita N, Baba M, Matsuyama T: Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003; 101: 3581-3589.
262. Bellinghausen I, Konig B, Bottcher I, Knop J, Saloga J: Inhibition of human allergic Thelper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction. Clin Exp Allergy 2006; 36: 1546-1555.
263. Maloy KJ, Powrie F: Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816-822.
264. Thunberg S, Akdis M, Akdis CA, Gronneberg R, Malmstrom V, Trollmo C, van Hage M, Gafvelin G: Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy 2007; 37: 1127-1136.
265. Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, Mi Z, Watkins SC, Gambotto A, Robbins PD: Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J Immunol 2005; 174: 6440-6448.
266. Bianco NR, Kim SH, Ruffner MA, Robbins PD: Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009; 60: 380-389.
267. Muller B, Daecke J, Fackler OT, Dittmar MT, Zentgraf H, Krausslich HG: Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J Virol 2004; 78: 10803-10813.
268. Stauber RH, Rulong S, Palm G, Tarasova NI: Direct visualization of HIV-1 entry: mechanisms and role of cell surface receptors. Biochem Biophys Res Commun 1999; 258: 695-702.
269. Yasuda K, Kosugi A, Hayashi F, Saitoh S, Nagafuku M, Mori Y, Ogata M, Hamaoka T: Serine 6 of Lck tyrosine kinase: a critical site for Lck myristoylation, membrane localization, and function in T lymphocytes. J Immunol 2000; 165: 3226-3231.
270. Zhou W, Parent LJ, Wills JW, Resh MD: Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol 1994; 68: 2556-2569.
271. Li H, Dou J, Ding L, Spearman P: Myristoylation is required for human immunodeficiency virus type 1 Gag-Gag multimerization in mammalian cells. J Virol 2007; 81: 12899-12910.
272. Thankamony SP, Knudson W: Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. J Biol Chem 2006; 281: 34601-34609.
273. Zhang W, Trible RP, Samelson LE: LAT palmitoylation: its essential role in membrane microdomain targeting and tyrosine phosphorylation during T cell activation. Immunity 1998; 9: 239-246.
274. Parenti M, Vigano MA, Newman CM, Milligan G, Magee AI: A novel N-terminal motif for palmitoylation of G-protein alpha subunits. Biochem J 1993; 291(pt 2):349-353.
275. Kabouridis PS, Magee AI, Ley SC: S-acylation of LCK protein tyrosine kinase is essential for its signalling function in T lymphocytes. EMBO J 1997; 16: 4983-4998.
276. Luetterforst R, Stang E, Zorzi N, Carozzi A, Way M, Parton RG: Molecular characterization of caveolin association with the Golgi complex: identification of a cis-Golgi targeting domain in the caveolin molecule. J Cell Biol 1999; 145: 1443-1459.
277. Chen BJ, Takeda M, Lamb RA: Influenza virus hemagglutinin (H3 subtype) requires palmitoylation of its cytoplasmic tail for assembly: M1 proteins of two subtypes differ in their ability to support assembly. J Virol 2005; 79: 13673-13684.
278. Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, Conchonaud F, Marguet D, He HT, Hueber AO: Palmitoylation is required for efficient Fas cell death signaling. EMBO J 2007; 26: 209-220.
279. Ziegler-Heitbrock HW, Ulevitch RJ: CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14: 121-125.
280. Ravetch JV, Perussia B: Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils: cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170: 481-497.
281. Selvaraj P, Rosse WF, Silber R, Springer TA: The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature 1988; 333: 565-567.
282. Classon BJ, Williams AF, Willis AC, Seed B, Stamenkovic I: The primary structure of the human leukocyte antigen CD37, a species homologue of the rat MRC OX-44 antigen. J Exp Med 1989; 169: 1497-1502.
283. Amiot M: Identification and analysis of cDNA clones encoding CD53: a pan-leukocyte antigen related to membrane transport proteins. J Immunol 1990; 145: 4322-4325.
284. Selvaraj P, Dustin ML, Silber R, Low MG, Springer TA: Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria: functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med 1987; 166: 1011-1025.
285. Porter JA, Ekker SC, Park WJ, von Kessler DP, Young KE, Chen CH, Ma Y, Woods AS, Cotter RJ, Koonin EV, Beachy PA: Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Cell 1996; 86: 21-34.
286. Porter JA, Young KE, Beachy PA: Cholesterol modification of hedgehog signaling proteins in animal development. Science 1996; 274: 255-259.
287. Mann RK, Beachy PA: Cholesterol modification of proteins. Biochim Biophys Acta 2000; 1529: 188-202.
288. Karpen HE, Bukowski JT, Hughes T, Gratton JP, Sessa WC, Gailani MR: The sonic hedgehog receptor patched associates with caveolin-1 in cholesterol-rich microdomains of the plasma membrane. J Biol Chem 2001; 276: 19503-19511.
289. Beekman JM, Bakema JE, van de Winkel JG, Leusen JH: Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity. Proc Natl Acad Sci USA 2004; 101: 10392-10397.
290. Langhorst MF, Reuter A, Stuermer CA: Scaffolding microdomains and beyond: the function of reggie/flotillin proteins. Cell Mol Life Sci 2005; 62: 2228-2240.
291. Parton RG, Hanzal-Bayer M, Hancock JF: Biogenesis of caveolae: a structural model for caveolin-induced domain formation. J Cell Sci 2006; 119: 787-796.
292. Beekman JM, van der Linden JA, van de Winkel JG, Leusen JH: FcgammaRI (CD64) resides constitutively in lipid rafts. Immunol Lett 2008; 116: 149-155.
293. Li H, Papadopoulos V: Peripheral-type benzodiazepine receptor function in cholesterol transport: identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology 1998; 139: 4991-4997.
294. Palmer M: Cholesterol and the activity of bacterial toxins. FEMS Microbiol Lett 2004; 238: 281-289.
295. Li H, Yao Z, Degenhardt B, Teper G, Papadopoulos V: Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci USA 2001; 98: 1267-1272.
296. Jamin N, Neumann JM, Ostuni MA, Vu TK, Yao ZX, Murail S, Robert JC, Giatzakis C, Papadopoulos V, Lacapere JJ: Characterization of the cholesterol recognition amino acid consensus sequence of the peripheral- type benzodiazepine receptor. Mol Endocrinol 2005; 19: 588-594.
297. Takimoto T, Portner A: Molecular mechanism of paramyxovirus budding. Virus Res 2004; 106: 133-145.
298. Pantua HD, McGinnes LW, Peeples ME, Morrison TG: Requirements for the assembly and release of Newcastle disease viruslike particles. J Virol 2006; 80: 11062-11073.
299. Shnyrova AV, Ayllon J, Mikhalyov II, Villar E, Zimmerberg J, Frolov VA: Vesicle formation by self-assembly of membrane-bound matrix proteins into a fluidlike budding domain. J Cell Biol 2007; 179: 627-633.
300. McCurdy LH, Graham BS: Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation. J Virol 2003; 77: 1747-1756.
301. Marty A, Meanger J, Mills J, Shields B, Ghildyal R: Association of matrix protein of respiratory syncytial virus with the host cell membrane of infected cells. Arch Virol 2004; 149: 199-210.
302. Fleming EH, Kolokoltsov AA, Davey RA, Nichols JE, Roberts NJ Jr: Respiratory syncytial virus F envelope protein associates with lipid rafts without a requirement for other virus proteins. J Virol 2006; 80: 12160-12170.
303. Oomens AG, Bevis KP, Wertz GW: The cytoplasmic tail of the human respiratory syncytial virus F protein plays critical roles in cellular localization of the F protein and infectious progeny production. J Virol 2006; 80: 10465-10477.
304. Batonick M, Oomens AG, Wertz GW: Human respiratory syncytial virus glycoproteins are not required for apical targeting and release from polarized epithelial cells. J Virol 2008; 82: 8664-8672.
305. Pohl C, Duprex WP, Krohne G, Rima BK, Schneider-Schaulies S: Measles virus M and F proteins associate with detergent-resistant membrane fractions and promote formation of virus-like particles. J Gen Virol 2007; 88: 1243-1250.
306. Takimoto T, Murti KG, Bousse T, Scroggs RA, Portner A: Role of matrix and fusion proteins in budding of Sendai virus. J Virol 2001; 75: 11384-11391.
307. Schmitt AP, Leser GP, Waning DL, Lamb RA: Requirements for budding of paramyxovirus simian virus 5 virus-like particles. J Virol 2002; 76: 3952-3964.
308. Gosselin-Grenet AS, Mottet-Osman G, Roux L: From assembly to virus particle budding: pertinence of the detergent resistant membranes. Virology 2006; 344: 296-303.
309. Irie T, Nagata N, Yoshida T, Sakaguchi T: Recruitment of Alix/AIP1 to the plasma membrane by Sendai virus C protein facilitates budding of virus-like particles. Virology 2008; 371: 108-120.
310. Brown EL, Lyles DS: Organization of the vesicular stomatitis virus glycoprotein into membrane microdomains occurs independently of intracellular viral components. J Virol 2003; 77: 3985-3992.
311. Irie T, Licata JM, Jayakar HR, Whitt MA, Bell P, Harty RN: Functional analysis of late-budding domain activity associated with the PSAP motif within the vesicular stomatitis virus M protein. J Virol 2004; 78: 7823-7827.
312. Swinteck BD, Lyles DS: Plasma membrane microdomains containing vesicular stomatitis virus M protein are separate from microdomains containing G protein and nucleocapsids. J Virol 2008; 82: 5536-5547.
313. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, Geisbert TW, Hevey M, Schmaljohn C, Schmaljohn A, Aman MJ: Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 2002; 195: 593-602.
314. Kolesnikova L, Berghofer B, Bamberg S, Becker S: Multivesicular bodies as a platform for formation of the Marburg virus envelope. J Virol 2004; 78: 12277-12287.
315. Kolesnikova L, Strecker T, Morita E, Zielecki F, Mittler E, Crump C, Becker S: Vacuolar protein sorting pathway contributes to the release of Marburg virus. J Virol 2009; 83: 2327-2337.
316. Freed EO: Virology: rafting with Ebola. Science 2002; 296: 279.
317. Aman MJ, Bosio CM, Panchal RG, Burnett JC, Schmaljohn A, Bavari S: Molecular mechanisms of filovirus cellular trafficking. Microbes Infect 2003; 5: 639-649.
318. Dolnik O, Kolesnikova L, Becker S: Filoviruses: interactions with the host cell. Cell Mol Life Sci 2008; 65: 756-776.
319. Gomez-Puertas P, Albo C, Perez-Pastrana E, Vivo A, Portela A: Influenza virus matrix protein is the major driving force in virus budding. J Virol 2000; 74: 11538-11547.
320. Leser GP, Lamb RA: Influenza virus assembly and budding in raft-derived microdomains: a quantitative analysis of the surface distribution of HA, NA and M2 proteins. Virology 2005; 342: 215-227.
321. Chen BJ, Leser GP, Morita E, Lamb RA: Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid- derived virus-like particles. J Virol 2007; 81: 7111-7123.
322. Radyukhin V, Fedorova N, Ksenofontov A, Serebryakova M, Baratova L: Cold co-extraction of hemagglutinin and matrix M1 protein from influenza virus A by a combination of non-ionic detergents allows for visualization of the raft-like nature of the virus envelope. Arch Virol 2008; 153: 1977-1980.
323. Henderson LE, Krutzsch HC, Oroszlan S: Myristyl amino-terminal acylation of murine retrovirus proteins: an unusual posttranslational proteins modification. Proc Natl Acad Sci USA 1983; 80: 339-343.
324. Spearman P, Wang JJ, Vander Heyden N, Ratner L: Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol 1994; 68: 3232-3242.
325. Morikawa Y, Hinata S, Tomoda H, Goto T, Nakai M, Aizawa C, Tanaka H, Omura S: Complete inhibition of human immunodeficiency virus Gag myristoylation is necessary for inhibition of particle budding. J Biol Chem 1996; 271: 2868-2873.
326. Bhattacharya J, Repik A, Clapham PR: Gag regulates association of human immunodeficiency virus type 1 envelope with detergent- resistant membranes. J Virol 2006; 80: 5292-5300.
327. Urano E, Aoki T, Futahashi Y, Murakami T, Morikawa Y, Yamamoto N, Komano J: Substitution of the myristoylation signal of human immunodeficiency virus type 1 Pr55Gag with the phospholipase C-delta1 pleckstrin homology domain results in infectious pseudovirion production. J Gen Virol 2008; 89: 3144-3149.
328. Jordan M, Schallhorn A, Wurm FM: Transfecting mammalian cells: optimization of critical parameters affecting calciumphosphate precipitate formation. Nucleic Acids Res 1996; 24: 596-601.
329. Yu F, Joshi SM, Ma YM, Kingston RL, Simon MN, Vogt VM: Characterization of Rous sarcoma virus Gag particles assembled in vitro. J Virol 2001; 75: 2753-2764.
330. Van Wauwe JP, De Mey JR, Goossens JG: OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 1980; 124: 2708-2713.
331. Meuer SC, Hodgdon JC, Hussey RE, Protentis JP, Schlossman SF, Reinherz EL: Antigen- like effects of monoclonal antibodies directed at receptors on human T cell clones. J Exp Med 1983; 158: 988-993.
332. Riddell SR, Greenberg PD: The use of anti- CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigenspecific T cells. J Immunol Methods 1990; 128: 189-201.
333. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP: Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003; 9: 619-624.
334. Maus MV, Riley JL, Kwok WW, Nepom GT, June CH: HLA tetramer-based artificial antigen- presenting cells for stimulation of CD4+ T cells. Clin Immunol 2003; 106: 16-22.
335. Delbrück A: Structural Chemistry and Molecular Biology. 1968: 168-215.
336. Brian AA, McConnell HM: Allogeneic stimulation of cytotoxic T cells by supported planar membranes. Proc Natl Acad Sci USA 1984; 81: 6159-6163.
337. Groves JT, Ulman N, Boxer SG: Micropatterning fluid lipid bilayers on solid supports. Science 1997; 275: 651-653.
338. Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N: Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 2009; 4:e4942.
339. Metzner C, Mostegl MM, Gunzburg WH, Salmons B, Dangerfield JA: Association of glycosylphosphatidylinositol-anchored protein with retroviral particles. FASEB J 2008; 22: 2734-2739.
340. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
341. Dudley ME, Rosenberg SA: Adoptive-celltransfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
342. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346-2357.
343. Robinson SP, Stagg AJ: Dendritic Cell Protocols. Humana Totowa, NJ 2001.
344. Davis ID, Jefford M, Parente P, Cebon J: Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003; 73: 3-29.
345. Gilboa E: DC-based cancer vaccines. J Clin Invest 2007; 117: 1195-1203.
346. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61: 6451-6458.
347. Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004; 10: 1359-1365.
348. Palucka AK, Dhodapkar MV, Paczesny S, Ueno H, Fay J, Banchereau J: Boosting vaccinations with peptide-pulsed CD34+ progenitor- derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother 2005; 28: 158-168.
349. Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, Ueno H, Banchereau J: Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 2006; 55: 1209-1218.
350. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N: Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233-238.
351. Jackson MR, Song ES, Yang Y, Peterson PA: Empty and peptide-containing conformers of class I major histocompatibility complex molecules expressed in Drosophila melanogaster cells. Proc Natl Acad Sci USA 1992; 89: 12117-12121.
352. Cai Z, Brunmark A, Jackson MR, Loh D, Peterson PA, Sprent J: Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc Natl Acad Sci USA 1996; 93: 14736-14741.
353. Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, Voland J, Jones V, Kan-Mitchell J: Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 2002; 20: 1075-1086.
354. Latouche JB, Sadelain M: Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000; 18: 405-409.
355. Papanicolaou GA, Latouche JB, Tan C, Dupont J, Stiles J, Pamer EG, Sadelain M: Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen- presenting cells expressing a single HLA allele. Blood 2003; 102: 2498-2505.
356. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20: 143-148.
357. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL: A cell-based artificial antigen- presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002; 105: 259-272.
358. Obermann S, Petrykowska S, Manns MP, Korangy F, Greten TF: Peptide-beta2- microglobulin-major histocompatibility complex expressing cells are potent antigen- presenting cells that can generate specific T cells. Immunology 2007; 122: 90-97.
359. Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stockl J, Herndler-Brandstetter D, Grubeck-Loebenstein B, Reipert BM, Pickl WF, Pfistershammer K, Steinberger P: The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008; 38: 2678-2688.